A phase I/IIa study of auceliciclib in patients with advanced solid tumours and in combination with temozolomide in patients with recurrent/relapsed high-grade glioma

Auceliciclib was well tolerated, and demonstrated dose-dependent pharmacokinetics and preliminary clinical activity in heavily pretreated patients. Recommended phase II doses are 500 mg twice daily (monotherapy) and 300 mg twice daily with 100 mg temozolomide once daily (combination therapy). These findings support further clinical development of auceliciclib for high-grade glioma and other malignancies.